A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

Trial Profile

A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 May 2018

At a glance

  • Drugs VS 5584 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Verastem Oncology
  • Most Recent Events

    • 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
    • 23 Dec 2016 Status changed from recruiting to discontinued.
    • 09 May 2016 According to a Verastem media release, the maximum tolerated dose has been reached and the recommended phase II dose is being confirmed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top